134 related articles for article (PubMed ID: 18391241)
1. Correlation between gene silencing activity and structural features of antisense oligodeoxynucleotides and target RNA.
Liao L; Li Z
In Silico Biol; 2007; 7(4-5):527-34. PubMed ID: 18391241
[TBL] [Abstract][Full Text] [Related]
2. Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.
't Hoen PA; Out R; Commandeur JN; Vermeulen NP; van Batenburg FH; Manoharan M; van Berkel TJ; Biessen EA; Bijsterbosch MK
RNA; 2002 Dec; 8(12):1572-83. PubMed ID: 12515389
[TBL] [Abstract][Full Text] [Related]
3. Optimization of antisense drug design against conservative local motif in simulant secondary structures of HER-2 mRNA and QSAR analysis.
Yang SP; Song ST; Tang ZM; Song HF
Acta Pharmacol Sin; 2003 Sep; 24(9):897-902. PubMed ID: 12956938
[TBL] [Abstract][Full Text] [Related]
4. ["Target secondary structural motif" in the action of antisense oligodeoxynucleotides].
Song HF; Tang ZM
Yao Xue Xue Bao; 2001 Aug; 36(8):585-9. PubMed ID: 12579934
[TBL] [Abstract][Full Text] [Related]
5. Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis.
Song HF; Tang ZM; Yuan SJ; Zhu BZ
Acta Pharmacol Sin; 2000 Jan; 21(1):80-6. PubMed ID: 11263253
[TBL] [Abstract][Full Text] [Related]
6. Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides.
Hasselblatt P; Hockenjos B; Thoma C; Blum HE; Offensperger WB
Nucleic Acids Res; 2005; 33(1):114-25. PubMed ID: 15640448
[TBL] [Abstract][Full Text] [Related]
7. Influence of mRNA self-structure on hybridization: computational tools for antisense sequence selection.
Toschi N
Methods; 2000 Nov; 22(3):261-9. PubMed ID: 11071822
[TBL] [Abstract][Full Text] [Related]
8. Prediction of antisense oligonucleotide binding affinity to a structured RNA target.
Walton SP; Stephanopoulos GN; Yarmush ML; Roth CM
Biotechnol Bioeng; 1999 Oct; 65(1):1-9. PubMed ID: 10440665
[TBL] [Abstract][Full Text] [Related]
9. Identification of sequence motifs significantly associated with antisense activity.
McQuisten KA; Peek AS
BMC Bioinformatics; 2007 Jun; 8():184. PubMed ID: 17555590
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides: from design to therapeutic application.
Chan JH; Lim S; Wong WS
Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
[TBL] [Abstract][Full Text] [Related]
11. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
[TBL] [Abstract][Full Text] [Related]
12. Novel oligonucleotides containing two 3'-ends complementary to target mRNA show optimal gene-silencing activity.
Bhagat L; Putta MR; Wang D; Yu D; Lan T; Jiang W; Sun Z; Wang H; Tang JX; La Monica N; Kandimalla ER; Agrawal S
J Med Chem; 2011 Apr; 54(8):3027-36. PubMed ID: 21466154
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligodeoxynucleotide and ribozyme design.
Probst JC
Methods; 2000 Nov; 22(3):271-81. PubMed ID: 11071823
[TBL] [Abstract][Full Text] [Related]
14. X-ray analyses of hybrid duplexes between antisense oligonucleotides containing 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine and their target RNAs.
Juan EC; Kondo J; Ito T; Ueno Y; Matsuda A; Takénaka A
Nucleic Acids Symp Ser (Oxf); 2005; (49):65-6. PubMed ID: 17150635
[TBL] [Abstract][Full Text] [Related]
15. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.
Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M
J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648
[TBL] [Abstract][Full Text] [Related]
16. Fundamental differences in the equilibrium considerations for siRNA and antisense oligodeoxynucleotide design.
Lu ZJ; Mathews DH
Nucleic Acids Res; 2008 Jun; 36(11):3738-45. PubMed ID: 18483081
[TBL] [Abstract][Full Text] [Related]
17. High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides.
Low J; Shuguang Huang ; Dowless M; Blosser W; Vincent T; Davis S; Hodson J; Koller E; Marcusson E; Blanchard K; Stancato L
J Biomol Screen; 2007 Sep; 12(6):775-88. PubMed ID: 17517903
[TBL] [Abstract][Full Text] [Related]
18. Antisense strategies in degenerative joint diseases: sense or nonsense?
Huber LC; Distler O; Gay RE; Gay S
Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
[TBL] [Abstract][Full Text] [Related]
19. Antisense radiotherapy: targeting full-size mdrl mRNA with 125I-labelled oligonucleotides.
Gaidamakova EK; Neumann RD; Panyutin IG
Int J Radiat Biol; 2004; 80(11-12):889-93. PubMed ID: 15764398
[TBL] [Abstract][Full Text] [Related]
20. Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA.
Walton SP; Stephanopoulos GN; Yarmush ML; Roth CM
Biophys J; 2002 Jan; 82(1 Pt 1):366-77. PubMed ID: 11751323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
